Skip to main content

Advertisement

SpringerLink
Log in

Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Proinflammatory markers, including neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), are associated with many aspects of different malignancies. The aim of this study was to assess the associations of NLR and PLR with estrogen receptor (ER) and progesterone receptor (PR) expression in locally advanced breast cancer patients and their changes after neoadjuvant chemotherapy (NAC). Whether these parameters were predictive for the response to NAC in breast cancer patients was also evaluated.

Methods

132 Female primary locally advanced breast cancer patients treated with either ET (epirubicin–docetaxel), TEC (docetaxel–epirubicin–cyclophosphamide), or CEF (cyclophosphamide–epirubicin–fluorouracil) as NAC were retrospectively studied. NLR and PLR were calculated from peripheral blood cell count and their optimal cutoff levels were determined by receiver operating characteristic curves.

Results

The proportion of ER-positive breast cancers before NAC was higher both in NLRlow (<2.05) group and PLRlow group (<159.01). Changes in ER or PR expression level or status were observed in some patients. The alterations of NLR and PLR after NAC correlated with chemotherapy regimens, and elevated PLR was found. The patients with low pretreatment NLR (<1.67) or PLR (<151.27) had better responses to NAC than those with high NLR (≥1.67, 67.3 vs. 47.1%, P < 0.05) or PLR (≥151.27, 64.0 vs. 45.1%, P < 0.05).

Conclusions

The patients with low pretreatment NLR (<2.05) or PLR (<159.01) had higher ER expression. Changes in ER and PR expression status or level occured following NAC. Elevated PLR was found aft-NAC. Pretreatment NLR and PLR may be important predictive indicators for NAC response in breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Sinacki M, Badzio A, Welnicka-Jaskiewicz M, Bogaerts J, Piccart MJ, Therasse P, et al. Pattern of care in locally advanced breast cancer: focus on local therapy. Breast. 2011;20(2):145–50. doi:10.1016/j.breast.2010.08.008.

    Article  PubMed  Google Scholar 

  2. Chavez-MacGregor M, Gonzalez-Angulo AM. Breast cancer, neoadjuvant chemotherapy and residual disease. Clin Transl Oncol. 2010;12(7):461–7. doi:10.1007/s12094-010-0538-0.

    Article  CAS  PubMed  Google Scholar 

  3. Mayer EL, Carey LA, Burstein HJ. Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res. 2007;9(5):110. doi:10.1186/bcr1755.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Zhou X, Zhang J, Yun H, Shi R, Wang Y, Wang W, et al. Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration. Oncotarget. 2015;6(34):36894–902. doi:10.18632/oncotarget.5050.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Cockburn A, Yan J, Rahardja D, Euhus D, Peng Y, Fang Y, et al. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer. Hum Pathol. 2014;45(2):249–58. doi:10.1016/j.humpath.2013.09.002.

    Article  CAS  PubMed  Google Scholar 

  6. Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res. 2011;31(9):2995–8.

    PubMed  Google Scholar 

  7. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer. 2013;109(2):401–7. doi:10.1038/bjc.2013.350.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rossi L, Santoni M, Crabb SJ, Scarpi E, Burattini L, Chau C, et al. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol. 2015;22(4):1377–84. doi:10.1245/s10434-014-4097-4.

    Article  PubMed  Google Scholar 

  9. Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long J, et al. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol. 2015;22(2):670–6. doi:10.1245/s10434-014-4021-y.

    Article  PubMed  Google Scholar 

  10. Ulas A, Avci N, Kos T, Cubukcu E, Olmez OF, Bulut N, et al. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab? J BUON. 2015;20(3):714–22.

    PubMed  Google Scholar 

  11. Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel. J BUON. 2013;18(1):57–63.

    CAS  PubMed  Google Scholar 

  12. Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6(4):195–7. doi:10.1200/JOP.777003.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Cohen DA, Dabbs DJ, Cooper KL, Amin M, Jones TE, Jones MW, et al. Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma. Am J Clin Pathol. 2012;138(6):796–802. doi:10.1309/AJCP6DKRND5CKVDD.

    Article  CAS  PubMed  Google Scholar 

  14. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–72. doi:10.1043/1543-2165-134.7.e48.

    Article  CAS  PubMed  Google Scholar 

  15. Avci N, Deligonul A, Tolunay S, Cubukcu E, Olmez OF, Ulas A, et al. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. J BUON. 2015;20(1):45–9.

    PubMed  Google Scholar 

  16. Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E, et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res. 2008;28(3B):1797–804.

    PubMed  Google Scholar 

  17. Lee SH, Chung MA, Quddus MR, Steinhoff MM, Cady B. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg. 2003;186(4):348–50.

    Article  CAS  Google Scholar 

  18. Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, et al. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer. 2003;10(1):91–8.

    Article  CAS  Google Scholar 

  19. Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, Zamagni C, et al. Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Res Treat. 2012;132(3):843–51. doi:10.1007/s10549-011-1660-6.

    Article  CAS  PubMed  Google Scholar 

  20. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. doi:10.1038/nature01322.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan GH, See MH, et al. Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113(1):150–8. doi:10.1038/bjc.2015.183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer. 2013;16(1):55–9. doi:10.4048/jbc.2013.16.1.55.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19(1):217–24. doi:10.1245/s10434-011-1814-0.

    Article  PubMed  Google Scholar 

  24. Yao M, Liu Y, Jin H, Liu X, Lv K, Wei H, et al. Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Onco Targets Ther. 2014;7:1743–52. doi:10.2147/OTT.S69657.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013;30(1):432. doi:10.1007/s12032-012-0432-4.

    Article  PubMed  Google Scholar 

  26. Suppan C, Bjelic-Radisic V, La Garde M, Groselj-Strele A, Eberhard K, Samonigg H, et al. Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy. BMC Cancer. 2015;15:1027. doi:10.1186/s12885-015-2005-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, et al. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol. 2016;23(4):1104–10. doi:10.1245/s10434-015-4934-0.

    Article  PubMed  Google Scholar 

  28. Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong C, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer. 2016;16:320. doi:10.1186/s12885-016-2352-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Eryilmaz MK, Mutlu H, Salim DK, Musri FY, Tural D, Coskun HS. The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. Asian Pac J Cancer Prev. 2014;15(18):7737–40.

    Article  Google Scholar 

  30. Adachi K, Sakurai K, Suzuki S, Hara Y, Nagashima S, Hirano T, et al. Study of the response rate and neutrophil lymphocyte ratio in breast cancer patients undergoing neoadjuvant chemotherapy. Gan To Kagaku Ryoho. 2015;42(10):1283–5.

    PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Grants from the National Natural Science Foundation of China (No. 81502615, No. 31470885, No. 31300752 and No. 31270971).

Author information

Authors and Affiliations

  1. Institute of Basic Medical Sciences, Qilu Hospital of Shandong University, #107 West Wenhua Road, Jinan, 250012, Shandong, People’s Republic of China

    J. Xu, C. Ma, L. Zhang, X. Jing, C. Li & X. Qu

  2. Department of Medical Oncology, Tai’an City Central Hospital, Tai’an, 271000, Shandong, People’s Republic of China

    J. Xu & C. Ni

  3. Department of Medical Oncology, Qilu Hospital of Shandong University, #107 West Wenhua Road, Jinan, 250012, Shandong, People’s Republic of China

    Y. Liu

Authors
  1. J. Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. X. Jing
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. X. Qu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Y. Liu or X. Qu.

Ethics declarations

Conflict of interest

All authors declared no conflict of interest.

Ethical standards

This study was approved by hospital medical ethics committee of the Tai’an City Central Hospital and Qilu Hospital of Shandong University.

Electronic supplementary material

Below is the link to the electronic supplementary material.

12094_2017_1630_MOESM1_ESM.tif

Supplementary Fig. 1 Representative pictures of different degrees of ER expression (negative/-, +, ++and +++) by immunohistochemistry (×200). Upper panel, ER expression before NAC; lower panel, ER expression after NAC. (TIFF 12936 kb)

12094_2017_1630_MOESM2_ESM.tif

Supplementary Fig. 2 Representative pictures of different degrees of PR expression (negative/-, +, ++and +++) by immunohistochemistry (×200). Upper panel, PR expression before NAC; lower panel, PR expression after NAC. (TIFF 13099 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, J., Ni, C., Ma, C. et al. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy. Clin Transl Oncol 19, 989–996 (2017). https://doi.org/10.1007/s12094-017-1630-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-017-1630-5

Keywords

Search

Navigation